AZD-5423

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
AZD-5423
AZD5423 structure.svg
Identifiers
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.205.965 Edit this at Wikidata
Chemical and physical data
FormulaC25H21F4N3O3
Molar mass487.446 g/mol g·mol−1
3D model (JSmol)

AZD-5423 is a nonsteroidal glucocorticoid and phase II experimental drug being developed by AstraZeneca and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat respiratory diseases and in particular chronic obstructive pulmonary disease.[1][2][3][4][5]

See also[edit]

References[edit]

External links[edit]